Cargando…
Co-expression and prognosis analyses of GLUT1–4 and RB1 in breast cancer
BACKGROUND: Current treatment methods for patients with triple-negative breast cancer (TNBC) are very limited, and the prognosis of TNBC is relatively poor. It has been reported that glucose transporter 1 (GLUT1) is overexpressed in breast cancer cells; however, its association with the prognosis is...
Autores principales: | Zhang, Xiaodan, Pang, Xiaocong, Zhang, Zhuo, Liu, Qianxin, Zhang, Hanxu, Xiang, Qian, Cui, Yimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442321/ https://www.ncbi.nlm.nih.gov/pubmed/34525987 http://dx.doi.org/10.1186/s12885-021-08763-y |
Ejemplares similares
-
Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021) -
Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019) -
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
por: Wu, Qin, et al.
Publicado: (2020) -
Functional Analyse of GLUT1 and GLUT12 in Glucose Uptake in Goat Mammary Gland Epithelial Cells
por: Yu, Qinghua, et al.
Publicado: (2013) -
Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials
por: Hou, Jingyi, et al.
Publicado: (2023)